US EditionMerck spends $10 billion for Verona, gaining access to its COPD medication
UNITED STATES, JUL 9 – Merck’s $10 billion acquisition of Verona Pharma adds Ohtuvayre, a novel COPD drug addressing a key unmet need, with over 96% of Verona’s revenue from this therapy.
- Merck aims to diversify revenue as Keytruda's patents expire, targeting acquisitions in the $10–$15 billion range, with CEO Robert Davis seeking strategic growth ahead of patent losses.
- Following the deal announcement, Verona's shares surged about 20%, while Merck's stock increased 25 cents to $81.63 in premarket trading Wednesday.
- Merck expects to close the acquisition in Q4 2025, adding Ohtuvayre to its cardio-pulmonary pipeline to support future revenue growth.
44 Articles
44 Articles
Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona Pharma
Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive pulmonary disease. While Ohtuvayre is projected to become a blockbuster product in COPD alone, its potential extends to other respiratory disorders as well. The post Merck Breathes Life Into Its Respiratory Prospects With $10B Deal to Buy Verona Pharma appeared first on MedCity News.
Madrid. The US pharmaceutical company Merck & Co., known outside the United States and Canada as MSD, announced on Wednesday that it will buy for about $10 billion (€8.544 million) the British biotechnology company Verona Pharma, specialized in respiratory ailments. According to a press release, Merck will be made with the English firm through a subsidiary after paying $107 (€91.42) for each ADS, equivalent to about eight ordinary shares of Vero…
Coverage Details
Bias Distribution
- 53% of the sources are Center
To view factuality data please Upgrade to Premium
